Alveofact 50mg Injection

• Neonatal respiratory distress syndrome (RDS)
• Meconium aspiration syndrome
• Pneumonia
• Acute respiratory distress syndrome (ARDS)
• Lung surfactant deficiency

Alveofact 50mg Injection reduces surface tension at the air-liquid interface in the lungs' alveoli, preventing collapse during exhalation and ensuring these tiny air sacs stay open for gas exchange. Composed of lipids and proteins, it enhances lung compliance, making breathing easier. In conditions like respiratory distress syndrome (RDS) or surfactant deficiencies, surfactant replacement therapy supplements or replaces insufficient surfactant, improving lung function and preventing breathing complications.

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with the Alveofact 50mg Injection, reducing effectiveness by causing undesirable side effects. 

• Stored at controlled room temperature, between 2°C to 8°C
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep away from children and pets.

Alveofact 50mg Injection should be used only when there is enough facility for ventilation and monitoring. This medicine should be administered via the intra-tracheal route. Your baby’s physician and nurse should constantly monitor to ensure that the right amount of oxygen is given. Dosing shall be stopped by the physician in case of a slow heartbeat or reduced oxygen in circulation and resumed only after the condition is stable.

Alveofact 50mg Injection causes some side effects like all medications, although not everyone will experience them. 

Serious:

• Airway blockage
• Infection
• Allergic reactions
• Pulmonary hemorrhage

Common:

• Transient oxygen desaturation
• Changes in heart rate
• Breathing difficulties

Ensure Alveofact 50mg Injection administration is conducted by trained healthcare professionals familiar with the procedure to minimize the risk of complications. Have proper ventilatory support available before and during administration to manage potential changes in oxygen levels or breathing difficulties. Continuously monitor your vital signs, oxygen levels, and respiratory status during and after administration to promptly address any adverse reactions or complications. Adhere strictly to aseptic techniques during administration to minimize the risk of infection. Ensure proper patient positioning to facilitate the administration process and minimize the risk of aspiration or airway obstruction. Conduct a thorough risk assessment, especially in cases of underlying lung conditions or compromised respiratory function, to determine surfactant therapy's potential benefits and risks.